THE ULTIMATE GUIDE TO SB-674042

quinupristin/dalfopristin will enhance the level or effect of sparsentan by affecting hepatic/intestinal enzyme CYP3A4 metabolism.It inhibits bacterial protein synthesis. The mixture of quinupristin and dalfopristin isn't Lively versus Enterococcus faecalis and needs to be given in combination with other antibacterials for mixed bacterial infection